VICTORIA, BC, Sept. 1, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE:
TQB2), a leader in full-service, therapeutic antibody discovery and
development, today reports that, pursuant to the Company's Stock
Option Plan, the Board of Directors has authorized the granting of
incentive stock options to executive management of the Company to
acquire an aggregate of 1,350,000 common shares of the Company. The
options have an exercise price of $1.70 per share, expire five years from the date
of grant and are subject to certain vesting requirements.
![ImmunoPrecise Antibodies Ltd. Logo (CNW Group/ImmunoPrecise Antibodies Ltd.) ImmunoPrecise Antibodies Ltd. Logo (CNW Group/ImmunoPrecise Antibodies Ltd.)](https://mma.prnewswire.com/media/1246687/ImmunoPrecise_Antibodies_Ltd__ImmunoPrecise_Antibodies_Grants_St.jpg)
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a
global technology platform company with end-to-end solutions
empowering companies to discover and develop therapies against any
disease. The Company's experience and cutting-edge technologies
enable unparalleled support of its partners in their quest to bring
innovative treatments to the clinic. ImmunoPrecise's full-service
capabilities dramatically reduce the time required for, and the
inherent risk associated with, conventional multi-vendor product
development. For further information, visit www.immunoprecise.com
or contact solutions@immunoprecise.com.
Forward Looking Information
This news release
contains statements that, to the extent they are not recitations of
historical fact, may constitute "forward-looking statements" within
the meaning of applicable Canadian securities laws. The Company
uses words such as "may", "would", "could", "will", "likely",
"expect", "believe", "intend", "should" and similar expressions to
identify forward-looking statements. Any such forward-looking
statements are based on assumptions and analyses made by
ImmunoPrecise in light of its experience and its perception of
historical trends, current conditions and expected future
developments. However, whether actual results and developments will
conform to ImmunoPrecise's expectations and predictions is subject
to any number of risks, assumptions and uncertainties. Many factors
could cause ImmunoPrecise's actual results to differ materially
from those expressed or implied by the forward-looking statements
contained in this news release. Such factors include, among other
things, actual revenues and earnings for IPA being lower than
anticipated, and those risks and uncertainties described in
ImmunoPrecise's annual management discussion and analysis for the
previous quarter ended January 31,
2020 which can be accessed at www.sedar.com.
The "forward-looking statements" contained herein speak only as of
the date of this press release and, unless required by applicable
law, ImmunoPrecise undertakes no obligation to publicly update or
revise such information, whether as a result of new information,
future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.